Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema; the key treatment goals are to protect the skin barrier, reduce inflammation, and alleviate itch. Topical corticosteroids are often effective for mild AD but have safety, tolerability, and compliance issues. More-effective therapies for topical-refractory and moderate to severe AD are needed. Pfizer’s Eucrisa and Sanofi / Regeneron’s Dupixent were first-to-market in an ongoing AD treatment revolution, with three new topical agents (Japan Tobacco et al.’s Corectim; Otsuka et al.’s Moizerto; Incyte’s Opzelura), one biologic (LEO’s Adtralza), and three JAK inhibitors (AbbVie’s Rinvoq, Eli Lilly’s Olumiant, and Pfizer’s Cibinqo) earning their first approvals in 2020-2021. This report provides a comprehensive analysis of AD patient populations, current disease management, unmet needs, and the clinical and commercial potential of emerging drugs.
QUESTIONS ANSWERED
What are the sizes of the mild, moderate, and severe AD subpopulations? How will they change by 2030? How well are these subpopulations served by current AD therapies?
How have Eucrisa and Dupixent been incorporated into the AD treatment algorithm? What market niches will newer-to-market agents occupy?
What emerging therapies are in development for AD? Of these therapies, which are best poised to achieve commercial success?
What are the greatest unmet treatment needs for AD, and to what degree will therapies in the pipeline address these needs?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.